Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
370 Leser
Artikel bewerten:
(1)

Precision Value & Health Acquires Global Omnichannel Engagement Leader, Across Health

EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies

BETHESDA, Md., March 24, 2021 /PRNewswire/ -- Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company's solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision's medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.

Founded in 2008 and headquartered in Belgium, Across Health partners with blue-chip life science clients to design, execute, and track omnichannel strategies and digital transformation programs. The foundation of Across Health's solutions is their market-leading Navigator365 product suite, a SaaS-based analytical platform for omnichannel launch planning, campaign strategy formulation, resource allocation, and impact measurement. These innovative products are complemented by decades of deep industry consulting expertise that helps clients develop a measurably effective omnichannel strategy - for launch, and throughout the entire commercialization life cycle.

Commenting on the acquisition, Precision Value & Health's EVP, Physician and Patient Engagement, Carolyn Morgan explains "The cultural fit between our teams was immediate and collaboration began almost instinctively. Across Health is built around a family of proprietary products that helps clients optimize their go-to-market strategy and resources using a uniquely actionable analytical framework. Their expertise, plus the Navigator365, allows us to step into a new level of evidence-based omnichannel customer engagement that will drive better decision making, and even greater success, for our clients."

Across Health's founder and CEO, Fonny Schenck says, "For years we have honed our pragmatic, evidence-based, end-to-end products and consultative insights to accelerate digital transformation and optimize the omnichannel go-to-market model for leading life science companies. This laser-sharp focus has resulted in broad customer adoption (16 of top 20 biopharma are clients) and excellent customer feedback (2020 NPS = 74). We are excited to team up with Precision Value & Health, so that we can better serve our current and future clients across the globe with a complete range of offerings."

Technology Holdings served as the exclusive financial advisor to Across Health. To find out more about Across Health's proprietary end-to-end omnichannel consultancy services and the Navigator365 and Scala365 product suites, please visit the website at https://www.across.health/

About Precision Value & Health
Precision Value & Health is engineered to bring specialized expertise to every juncture of the innovation and commercialization continuum. With teams harnessing data-driven evidence and leveraging real-world experience, Precision Value & Health partners with life science companies to establish and communicate the clinical, economic, and humanistic value of innovative therapies. Our commercialization capabilities include PRECISIONadvisors (global pricing and market access strategy), PRECISIONeffect (healthcare communications and marketing), PRECISIONheor (evidence generation and strategy), PRECISIONscientia (medical communications), PRECISIONvalue (managed markets marketing), and PRECISIONxtract (data-driven analytics and insights) Precision Value & Health is shifting the trajectory and accelerating your success. Visit: www.precisionvaluehealth.com

Media Contact:
Louis Landon, Precision Medicine Group Media Relations
310-984-7707
louis.landon@precisionmedicinegrp.com

© 2021 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.